Evidence map›Paper›PMID 41013842›Full record

ArticleStem cell research & therapy2025

Clinical-grade allogeneic amniotic fluid stem cell banking: quality control for therapeutic applications and drug development.

Tatsanee Phermthai, Sasiprapa Thongbopit, Tuangsit Wataganara, Suparat Wichitwiengrat, Puttachart Chuaynarong, Juthakorn Poothong, Prasert Auewarakul

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tatsanee PhermthaiStem Cell Bank Unit, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Prannok Road, Siriraj, Bangkoknoi, Bangkok, 10700, Thailand. phermthai2515@gmail.com.
Sasiprapa ThongbopitStem Cell Bank Unit, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Prannok Road, Siriraj, Bangkoknoi, Bangkok, 10700, Thailand.
Tuangsit WataganaraDivision of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Suparat WichitwiengratStem Cell Bank Unit, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Prannok Road, Siriraj, Bangkoknoi, Bangkok, 10700, Thailand.
Puttachart ChuaynarongStem Cell Bank Unit, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Prannok Road, Siriraj, Bangkoknoi, Bangkok, 10700, Thailand.
Juthakorn PoothongStem Cell Bank Unit, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Prannok Road, Siriraj, Bangkoknoi, Bangkok, 10700, Thailand.
Prasert AuewarakulDepartment of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAllogeneic mesenchymal stem cells (MSCs) offer significant advantages for various medical treatments. However, maintaining an allogeneic MSC bank presents challenges due to concerns about heterogeneity, which directly affects their efficacy. Additionally, issues related to cell senescence can arise even after a short period of serial passaging. Amniotic fluid mesenchymal stem cells (AF-MSCs) demonstrate greater proliferation efficiency compared to other MSCs. They can form clonal cell lines that generate a homogeneous population and can expand in long-term cultures without undergoing cellular senescence. Therefore, this study introduces a method for establishing cell lines and a banking system for AF-MSCs, providing high-quality, authentic human MSCs for clinical applications.

methodsIn this research, we isolated clonal AF-MSCs to select them for the creation of AF-MSC stock through long-term serial passaging. We developed a three-tier cell banking system, which includes an AF-MSC stock, a Master Cell Bank at passage 4, and a Working Cell Bank at passage 9. Standard characteristics were employed to verify identity, safety, and quality control assessments.

resultsThree out of twelve AF-MSC clones were selected to exemplify cell line establishment, the creation of a three-tier banking system, and quality control evaluations to determine their suitability for clinical-grade cell lines in medical applications.

conclusionsThis study offers a comprehensive technical and translational overview of establishing an allogeneic amniotic fluid mesenchymal stem cell bank, tailored for medical applications and drug development.

Indexed as

Amniotic FluidDrug DevelopmentMesenchymal Stem CellsCell DifferentiationCell ProliferationFemaleHumansMesenchymal Stem Cell TransplantationQuality ControlCell manufacturingCharacterizationClonal cellMesenchymal stem cellRegeneration

Identifiers

PMID41013842
PMCPMC12465728

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.